Drug Trial Radar · NCT03010228
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Jan 31, 2017
Primary completion
Sep 28, 2017
Study completion Jan 16, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Valneva Austria GmbH
- First posted
- Jan 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 39 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Observer-blind, partially randomized, multi-center dose escalation Phase I study in healthy adults below 40 years of age. 180 subjects will be enrolled in 6 treatment groups (different doses; different formulation: with/without adjuvant); vaccinations will be given I.M.(intramuscular) into the deltoid region on Days 0, 28 and 56. Study participants will be followed up until one year after first vaccination. Booster Extension: Subjects in the 48µg and 90µg Treatment groups who received a complete Primary immunization schedule will be included into a Booster Extension 13 months after the first immunization.
Conditions
- Lyme Borreliosis, Nervous System
Interventions
VLA15 with AlumBiological
I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
VLA15 without AlumBiological
I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of SAEs to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
- Rate of related SAEs to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
- Rate of any solicited or unsolicited Grade 3 or Grade 4 events up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
- Rate of any solicited or related unsolicited Grade 3 or Grade 4 events up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
- Rate of solicited local AEs within 7 days after each and after any vaccination up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
- Rate of solicited systemic AEs within 7 days after each and after any vaccination up to Day 84Time frame: up to Day 84 (Month 3) after first vaccination
- Rate of unsolicited AEs to Day 84, including clinically significant laboratory parameter changesTime frame: up to Day 84 (Month 3) after first vaccination
- Rate of related unsolicited AEs to Day 84, including clinically significant laboratory parameter changesTime frame: up to Day 84 (Month 3) after first vaccination
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
eStudy Site
La Mesa, California
eStudySite
La Mesa, California
Celerion Inc.
Lincoln, Nebraska
Celerion, Inc
Lincoln, Nebraska
University Hospital Ghent
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.